Heterogeneous inflammatory changes in liver graft recipients with normal biochemistry

Transplantation

Volumn 89, Issue 6, 2010, Pages 739-748

  Gelson, William ^a   Hoare, Matthew ^a   Unitt, Esther ^a   Palmer, Christopher ^b   Gibbs, Paul ^b   Coleman, Nicholas ^b   Davies, Susan ^b   Alexander, Graeme J M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Immunosuppression.; Liver biopsy; Liver transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; CALCINEURIN INHIBITOR; LYMPHOCYTE SURFACE MARKER; RAPAMYCIN;

ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FIBROSIS; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER HILUS; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE;

ADULT; AGED; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; BILIRUBIN; BIOLOGICAL MARKERS; BIOPSY; CELL CYCLE PROTEINS; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; HEPATITIS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LYMPHOCYTES; MALE; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77949882262     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181c96b32     Document Type: Article

References (36)

1. Post DJ, Douglas DD, Mulligan DC. Immunosuppression in liver transplantation. Liver Transpl 2005; 11: 1307.
2. Geissler EK, Schlitt HJ. Immunosuppression for liver transplantation. Gut 2009; 58: 452.
3. Mazariegos GV, Reyes J, Marino IR, et al. Weaningof immunosuppres-sion in liver transplant recipients. Transplantation 1997; 63: 243.
4. Ramos HC, Reyes J, bu-Elmagd K, et al. Weaning of immunosuppres-sion in long-term liver transplant recipients. Transplantation 1995; 59: 212.
5. Manez R, Kusne S, Linden P, et al. Temporary withdrawal of immuno-suppression for life-threatening infections after liver transplantation. Transplantation 1994; 57: 149.
6. Massarollo PC, Mies S, Abdala E, et al. Immunosuppression withdrawal for treatment of severe infections in liver transplantation. Transplant Proc 1998; 30: 1472.
7. Lehner F, Becker T, Sybrecht L, et al. Successful outcome ofacute graft-versus-host disease in a liver allograft recipient by withdrawal of im-munosuppression. Transplantation 2002; 73: 307.
8. Mazariegos GV. Withdrawalofimmunosuppressionin liver transplantation: Lessons learned from PTLD. Pediatr Transplant 2004; 8: 210.
9. Eason JD, Cohen AJ, Nair S, et al. Tolerance: Is it worth the risk? Transplantation 2005; 79: 1157.
10. Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosup-pression in living donor liver transplant recipients. Transplantation 2001; 72: 449.
11. Oike F, Yokoi A, Nishimura E, et al. Complete withdrawal of immuno-suppressioninliving donor liver transplantation.Transplant Proc2002; 34: 1521.
12. Slapak GI, Saxena R, Portmann B, et al. Graft and systemic disease in long-term survivors of liver transplantation. Hepatology 1997; 25: 195.
13. Wong T, Nouri-Aria KT, Devlin J, et al. Tolerance and latent cellular rejection in long-term liver transplant recipients. Hepatology 1998; 28: 443.
14. Martinez-Llordella M, Lozano JJ, Puig-Pey I, et al. Using transcrip-tional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118: 2845.
15. Uemura T, Ikegami T, Sanchez EQ, et al. Late acute rejection after liver transplantation impacts patient survival. Clin Transplant 2008; 22: 316.
16. Anand AC, Hubscher SG, Gunson BK, et al. Timing, significance, and prognosis of late acute liver allograft rejection. Transplantation 1995; 60: 1098.
17. IshakK, BaptistaA, BianchiL, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696.
18. Hoare M, Gelson WT, Rushbrook SM, et al. Histological changes in HCV antibody-positive, HCV RNA-negative subjects suggest persistent virus infection. Hepatology 2008; 48: 1737.
19. Unitt E, Gelson W, Davies SE, et al. Minichromosome maintenance protein-2-positive portal tract lymphocytes distinguish acute cellular rejection from hepatitis C virus recurrence after liver transplantation. Liver Transpl 2009; 15: 306.
20. Mells G, Neuberger J. Protocol liver allograft biopsies. Transplantation 2008; 85: 1686.
21. HubscherSG. Chronic hepatitis in liver allografts. Hepatology 1990; 12: 1257.
22. Syn WK, Nightingale P, Gunson B, et al. Natural history of unexplained chronic hepatitis after liver transplantation. Liver Transpl 2007; 13: 984.
23. Miyagawa-Hayashino A, Haga H, Egawa H, et al. Idiopathic post-transplantation hepatitis following living donor liver transplantation, and significance of autoantibody titre for outcome. Transpl Int 2009; 22:303.
24. Robinson PW, Green SJ, Carter C, et al. Studies on transcriptional regulation of the mucosal T-cell integrin alphaEbeta7 (CD103). Immunology 2001; 103: 146.
25. Hadley GA, Rostapshova EA, Gomolka DM, et al. Regulation of the epithelial cell-specific integrin, CD103, by human CD8+ cytolytic T lymphocytes. Transplantation 1999; 67: 1418.
26. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199.
27. Roncarolo MG, Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells? Eur J Immunol 2008; 38: 925.
28. Stenard F, Nguyen C, Cox K, et al. Decreases in circulating CD4(+)CD25(hi)FOXP3(+) cells and increases in intragraft FOXP3(+) cells accompany allograft rejection in pediatric liver allograft recipients. Pediatr Transplant 2009; 13: 70.
29. Wang J, Ioan-Facsinay A, van der Voort EI, et al. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Im-munol2007; 37: 129.
30. Gavin MA, Torgerson TR, Houston E, et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 2006; 103: 6659.
31. Musahl C, Holthoff HP, LeschR, et al. Stability of the replicative Mcm3 protein in proliferating and differentiating human cells. Exp Cell Res 1998; 241: 260.
32. Sherr CJ. The Pezcoller lecture: Cancer cell cycles revisited. Cancer Res 2000; 60: 3689.
33. Soin AS, Rasmussen A, Jamieson NV, et al. CsA levels in the early posttransplant period\predictive of chronic rejection in liver transplantation? Transplantation 1995; 59: 1119.
34. Bathgate AJ, Hynd P, Sommerville D, et al. The prediction of acute cellular rejection in orthotopic liver transplantation. Liver Transpl Surg 1999; 5: 475.
35. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: Incidence, risk factors, and impact on outcome. Hepatology 1998; 28:638.
36. Klintmalm GB, Nery JR, Husberg BS, et al. Rejection in liver transplantation. Hepatology 1989; 10: 978.